News | July 10, 2008

St. Jude Gets CE Mark, Launches HydroSteer Guidewire with Hydrophilic Coating in Europe

July 11, 2008 - St. Jude Medical Inc. today received European CE Mark approval and began its European launch of its line of HydroSteer Hydrophilic-Coated Nitinol Guidewires.

The HydroSteer line of guidewires features a lubricious hydrophilic coating, which becomes slippery when wet, thereby reducing friction and enabling physicians to more easily maneuver the wires through the patient’s vessels. The HydroSteer line includes a wide variety of sizes, lengths and configurations.

The HydroSteer family is designed to provide physicians with more control of the guidewire’s tip, allowing the physician optimal placement of the subsequent procedural tools. Each wire in the HydroSteer line provides excellent steerability to help physicians navigate challenging vascular structures.

A guidewire is a thin, flexible wire that physicians use to help guide and steer a catheter (a flexible tube) through the vessels to deliver treatments, such as stents, which open blockages and restore blood flow to the heart or other parts of the body.

A radiopaque polymer jacket on the wire’s Nitinol (nickel-titanium alloy) core enhances the physician’s ability to visualize the wire’s location in the vessel. The wire’s Nitinol core resists kinking while providing the flexibility physicians need to advance the wire through the vasculature. In addition, the company said a torque device enhances steerability by aiding directional control. The torque device also has received CE Mark approval and is available for separate purchase, the company said.

For more information: www.sjm.com

Related Content

Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Intensive Glycemic Control Program Produces Significant Per-Patient Cost Savings for CABG Surgery
News | Cardiovascular Surgery| May 25, 2017
A new study from Emory University observed a near-20 percent reduction in perioperative complications, a 1.2-day...
Risk of Heart Transplant Rejection Reduced by Desensitizing Patient Antibodies
News | Cardiovascular Surgery| May 23, 2017
The risk of heart transplant rejection can be reduced by desensitizing patient antibodies, according to research...
Scientists Show How Cells React to Injury From Open-Heart Surgery
News | Cardiovascular Surgery| May 04, 2017
Cedars-Sinai Heart Institute investigators have learned how cardiac muscle cells react to a certain type of injury that...
ERACS Session Highlights Need for Standardized Best Practices in Cardiac Surgery
News | Cardiovascular Surgery| May 02, 2017
The recently formed group Enhanced Recovery After Cardiac Surgery (ERACS) hosted an organizing session in Boston on...
ClearFlow Receives Frost & Sullivan New Product Innovation Award for PleuraFlow Technology
News | Cardiovascular Surgery| May 01, 2017
ClearFlow Inc. has received the prestigious 2017 Global Frost & Sullivan Award for New Product Innovation. The...
Edwards Intuity Elite sutureless aortic valve, first implants in Connecticut, WCHN, Western Connecticut Health Network
News | Cardiovascular Surgery| February 16, 2017
Western Connecticut Health Network (WCHN) cardiothoracic surgeons Cary Passik, M.D., and Robert Gallagher, M.D., were...
open-heart surgery, PCI, percutaneous coronary intervention, NOBLE trial, left main coronary artery disease, LMCAD, TCT 2016
News | Cardiovascular Surgery| November 03, 2016
Coronary artery bypass (CABG) surgery is the standard treatment for revascularization in patients with left main...
Overlay Init